Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Bicara Therapeutics Inc. (BCAX) had Return on Tangible Equity of -9.31% for the most recently reported fiscal quarter, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-37.39M |
|
-- |
|
-- |
|
$41.12M |
|
$-41.12M |
|
$3.79M |
|
$-37.33M |
|
$-37.33M |
|
$-37.39M |
|
$-37.39M |
|
$-37.39M |
|
$-37.39M |
|
$-41.12M |
|
$-40.81M |
|
54.68M |
|
54.68M |
|
$-0.67 |
|
$-0.67 |
|
| Balance Sheet Financials | |
$422.05M |
|
$0.33M |
|
$8.94M |
|
$430.99M |
|
$28.95M |
|
-- |
|
$0.59M |
|
$29.54M |
|
$401.45M |
|
$401.45M |
|
$401.45M |
|
56.60M |
|
| Cash Flow Statement Financials | |
$-106.83M |
|
$-318.45M |
|
$32.26M |
|
$489.71M |
|
$96.69M |
|
$-393.03M |
|
$15.01M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
14.58 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-107.11M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-9.31% |
|
|
Return on Tangible Equity |
-9.31% |
-8.67% |
|
-9.31% |
|
$7.09 |
|
$-1.96 |
|
$-1.95 |
|